Stock Scorer

Tonix Pharmaceuticals Holding Corp. (TNXP)

Tonix Pharmaceuticals Holding Corp. reported revenue of 13.5M USD for the quarter ending 30 June 2026, up 577.9% from 2M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 13.5M +577.9%
Gross Profit Q2 '26 · ending 30 June 2026 12.8M —
Operating Income Q2 '26 · ending 30 June 2026 -42.5M —
Net Income Q2 '26 · ending 30 June 2026 -40.6M —
Cost of Revenue Q2 '26 · ending 30 June 2026 703K -78.5%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -42.2M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -42.8M —
Shares Outstanding Q2 '26 · ending 30 June 2026 16.6M +180.7%
EPS Q2 '26 · ending 30 June 2026 -13.11 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 13.1M-125.7M-124M-103.2M
20242024-12-31 10.1M-136.7M-130M-61M
20232023-12-31 7.8M-118.4M-116.7M-109.9M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-3013.5M
Q1 '262026-03-316.9M
Q4 '252025-12-315.4M
Q3 '252025-09-303.3M
Q2 '252025-06-302M
Q1 '252025-03-312.4M
Q4 '242024-12-312.6M
Q3 '242024-09-302.8M
Q2 '242024-06-302.2M
Q1 '242024-03-312.5M
Q4 '232023-12-313.8M
Q3 '232023-09-304M

Gross Profit Quarterly

Revenue minus cost of sales. This filer tags no gross profit of its own..

PeriodEndingGross Profit
Q2 '262026-06-3012.8M
Q1 '262026-03-315.3M
Q4 '252025-12-314.3M
Q3 '252025-09-301.9M
Q2 '252025-06-30-1.3M
Q1 '252025-03-311.5M
Q4 '242024-12-311.4M
Q3 '242024-09-301.3M
Q2 '242024-06-30-1.2M
Q1 '242024-03-31822K
Q4 '232023-12-311.4M
Q3 '232023-09-301.6M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-42.5M
Q1 '262026-03-31-41.5M
Q4 '252025-12-31-48.3M
Q3 '252025-09-30-33.1M
Q2 '252025-06-30-28.3M
Q1 '252025-03-31-16.1M
Q4 '242024-12-31-22.5M
Q3 '242024-09-30-15.6M
Q2 '242024-06-30-77.3M
Q1 '242024-03-31-21.4M
Q4 '232023-12-31-27.3M
Q3 '232023-09-30-28.1M
Q2 '232023-06-30-29M
Q1 '232023-03-31-33.9M
Q4 '222022-12-31-32.7M
Q3 '222022-09-30-29.6M
Q2 '222022-06-30-23.3M
Q1 '222022-03-31-26.4M
Q4 '212021-12-31-29.5M
Q3 '212021-09-30-18.5M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-40.6M
Q1 '262026-03-31-40.2M
Q4 '252025-12-31-46.9M
Q3 '252025-09-30-32M
Q2 '252025-06-30-28.3M
Q1 '252025-03-31-16.8M
Q4 '242024-12-31-22.1M
Q3 '242024-09-30-14.2M
Q2 '242024-06-30-78.8M
Q1 '242024-03-31-14.9M
Q4 '232023-12-31-27.3M
Q3 '232023-09-30-28M
Q2 '232023-06-30-28.4M
Q1 '232023-03-31-33M
Q4 '222022-12-31-31.7M
Q3 '222022-09-30-29M
Q2 '222022-06-30-23.1M
Q1 '222022-03-31-26.4M
Q4 '212021-12-31-29.6M
Q3 '212021-09-30-18.5M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-30703K
Q1 '262026-03-311.6M
Q4 '252025-12-311.1M
Q3 '252025-09-301.4M
Q2 '252025-06-303.3M
Q1 '252025-03-31943K
Q4 '242024-12-311.2M
Q3 '242024-09-301.6M
Q2 '242024-06-303.4M
Q1 '242024-03-311.7M
Q4 '232023-12-312.4M
Q3 '232023-09-302.4M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-42.2M
Q1 '262026-03-31-42.3M
Q4 '252025-12-31-39.6M
Q3 '252025-09-30-28.8M
Q2 '252025-06-30-14.8M
Q1 '252025-03-31-16.6M
Q4 '242024-12-31-14.6M
Q3 '242024-09-30-18.8M
Q2 '242024-06-30-9.9M
Q1 '242024-03-31-17.6M
Q4 '232023-12-31-22.3M
Q3 '232023-09-30-23.4M
Q2 '232023-06-30-23.4M
Q1 '232023-03-31-32.9M
Q4 '222022-12-31-22.3M
Q3 '222022-09-30-23.5M
Q2 '222022-06-30-21.2M
Q1 '222022-03-31-31M
Q4 '212021-12-31-22.4M
Q3 '212021-09-30-12.9M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-42.8M
Q1 '262026-03-31-44M
Q4 '252025-12-31-41.5M
Q3 '252025-09-30-29.7M
Q2 '252025-06-30-15.4M
Q1 '252025-03-31-16.6M
Q4 '242024-12-31-14.6M
Q3 '242024-09-30-18.8M
Q2 '242024-06-30-9.9M
Q1 '242024-03-31-17.7M
Q4 '232023-12-31-22.8M
Q3 '232023-09-30-25.2M
Q2 '232023-06-30-25.2M
Q1 '232023-03-31-36.7M
Q4 '222022-12-31-27M
Q3 '222022-09-30-32.4M
Q2 '222022-06-30-35.6M
Q1 '222022-03-31-51.3M
Q4 '212021-12-31-48.1M
Q3 '212021-09-30-20.7M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3016.6M
Q1 '262026-03-3113.7M
Q3 '252025-09-308.9M
Q2 '252025-06-307.3M
Q1 '252025-03-315.9M
Q3 '242024-09-30626.7K
Q2 '242024-06-3041K
Q1 '242024-03-3127.9K
Q3 '232023-09-30724.2K
Q2 '232023-06-30576K
Q1 '232023-03-3110.3M
Q3 '222022-09-306.8M
Q2 '222022-06-303.6M
Q1 '222022-03-3116.4M
Q3 '212021-09-3011.6M
Q2 '212021-06-3010.5M
Q1 '212021-03-31290.1M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-13.11
Q1 '262026-03-31-14.53
Q4 '252025-12-31-14.44
Q3 '242024-09-30-17056.03
Q2 '242024-06-30-17071.98
Q1 '242024-03-31-15200.36
Q4 '232023-12-31-14667.85
Q3 '232023-09-30-92.50
Q2 '232023-06-30-58.11
Q1 '232023-03-31-16.52
Q4 '222022-12-31-14.92
Q3 '222022-09-30-15.57
Q2 '222022-06-30-12.93
Q1 '222022-03-31-7.54
Q4 '212021-12-31-6.00
Q3 '212021-09-30-3.98
Q2 '212021-06-30-2.47
Q1 '212021-03-31-0.45
Q4 '202020-12-31-0.75
Q3 '202020-09-307.85